CABA
Cabaletta Bio Inc
NASDAQ: CABA · HEALTHCARE · BIOTECHNOLOGY
$2.78
-2.80% today
Updated 2026-04-29
Market cap
$328.40M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.10
Dividend yield
—
52W range
$1 – $4
Volume
2.2M
Cabaletta Bio Inc (CABA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
+2.2%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+38.5%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-4.8%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-6.4%
2026-03-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-12 | $-0.40 | +12.7% | $3.27 | $3.06 | -6.4% |
| 2025-11-10 | $-0.44 | +6.8% | $2.55 | $2.47 | -3.1% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.46 | $-0.40 | +12.7% | — | — |
| 2025-09-30 | $-0.47 | $-0.44 | +6.8% | — | — |
| 2025-06-30 | $-0.65 | $-0.73 | -12.3% | — | — |
| 2025-03-31 | $-0.66 | $-0.65 | +1.7% | — | — |
| 2024-12-31 | $-0.63 | $-0.65 | -3.8% | $1.64M | -59.2% |
| 2024-09-30 | $-0.60 | $-0.62 | -3.3% | — | — |
| 2024-06-30 | $-0.55 | $-0.56 | -1.8% | — | — |
| 2024-03-31 | $-0.48 | $-0.51 | -6.3% | — | — |
| 2023-12-31 | $-0.39 | $-0.46 | -17.9% | $4.01M | — |
| 2023-09-30 | $-0.40 | $-0.37 | +7.5% | — | — |
| 2023-06-30 | $-0.44 | $-0.37 | +15.9% | — | — |
| 2023-03-31 | $-0.48 | $-0.45 | +6.2% | — | — |
Frequently asked questions
Has Cabaletta Bio Inc beaten earnings estimates?
Cabaletta Bio Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of +2.2% over the last 4 quarters.
How does CABA stock react to earnings?
CABA stock has moved an average of -4.8% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.